Abstract
The efficacy and safety of consuming high-dose isoflavone supplements for prostate cancer is not clear. A double-blind, placebo controlled, randomized trial was conducted in 53 men with prostate cancer enrolled in an active surveillance program. The treatment group consumed a supplement containing 450 mg genistein, 300 mg daidzein, and other isoflavones daily for 6 mo. Prostate-specific antigen (PSA) was measured in both groups at baseline, 3 mo, and 6 mo, and serum concentrations of genistein, daidzein, and equol were assessed at baseline and 6 mo in the treatment group. Following the completion of the 6-mo double-blind study, men were enrolled in a 6-mo open label trial with the same isoflavone-rich supplement, and PSA was measured at 3 and 6 mo. PSA concentrations did not change in either group after 6 mo or after 12 mo when the open-label study was included. The 6 mo serum concentrations of genistein and daidzein (39.85 and 45.59 μmol/l, respectively) were significantly greater than baseline values and substantially higher than levels previously reported in other studies. Equol levels did not change. Although high amounts of aglycone isoflavones may result in significantly elevated serum concentrations of genistein and daidzein, these dietary supplements alone did not lower PSA levels in men with low-volume prostate cancer.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1036-1043 |
| Number of pages | 8 |
| Journal | Nutrition and Cancer |
| Volume | 62 |
| Issue number | 8 |
| DOIs | |
| State | Published - Nov 2010 |
Fingerprint
ASJC Scopus subject areas
- Medicine (miscellaneous)
- Nutrition and Dietetics
- Oncology
- Cancer Research
Cite this
Effects of a high dose, aglycone-rich soy extract on prostate-specific antigen and serum isoflavone concentrations in men with localized prostate cancer. / deVere White, Ralph W; Tsodikov, Alexander; Stapp, Eschelle C.; Soares, Stephanie E.; Fujii, Hajime; Hackman, Robert M.
In: Nutrition and Cancer, Vol. 62, No. 8, 11.2010, p. 1036-1043.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effects of a high dose, aglycone-rich soy extract on prostate-specific antigen and serum isoflavone concentrations in men with localized prostate cancer
AU - deVere White, Ralph W
AU - Tsodikov, Alexander
AU - Stapp, Eschelle C.
AU - Soares, Stephanie E.
AU - Fujii, Hajime
AU - Hackman, Robert M.
PY - 2010/11
Y1 - 2010/11
N2 - The efficacy and safety of consuming high-dose isoflavone supplements for prostate cancer is not clear. A double-blind, placebo controlled, randomized trial was conducted in 53 men with prostate cancer enrolled in an active surveillance program. The treatment group consumed a supplement containing 450 mg genistein, 300 mg daidzein, and other isoflavones daily for 6 mo. Prostate-specific antigen (PSA) was measured in both groups at baseline, 3 mo, and 6 mo, and serum concentrations of genistein, daidzein, and equol were assessed at baseline and 6 mo in the treatment group. Following the completion of the 6-mo double-blind study, men were enrolled in a 6-mo open label trial with the same isoflavone-rich supplement, and PSA was measured at 3 and 6 mo. PSA concentrations did not change in either group after 6 mo or after 12 mo when the open-label study was included. The 6 mo serum concentrations of genistein and daidzein (39.85 and 45.59 μmol/l, respectively) were significantly greater than baseline values and substantially higher than levels previously reported in other studies. Equol levels did not change. Although high amounts of aglycone isoflavones may result in significantly elevated serum concentrations of genistein and daidzein, these dietary supplements alone did not lower PSA levels in men with low-volume prostate cancer.
AB - The efficacy and safety of consuming high-dose isoflavone supplements for prostate cancer is not clear. A double-blind, placebo controlled, randomized trial was conducted in 53 men with prostate cancer enrolled in an active surveillance program. The treatment group consumed a supplement containing 450 mg genistein, 300 mg daidzein, and other isoflavones daily for 6 mo. Prostate-specific antigen (PSA) was measured in both groups at baseline, 3 mo, and 6 mo, and serum concentrations of genistein, daidzein, and equol were assessed at baseline and 6 mo in the treatment group. Following the completion of the 6-mo double-blind study, men were enrolled in a 6-mo open label trial with the same isoflavone-rich supplement, and PSA was measured at 3 and 6 mo. PSA concentrations did not change in either group after 6 mo or after 12 mo when the open-label study was included. The 6 mo serum concentrations of genistein and daidzein (39.85 and 45.59 μmol/l, respectively) were significantly greater than baseline values and substantially higher than levels previously reported in other studies. Equol levels did not change. Although high amounts of aglycone isoflavones may result in significantly elevated serum concentrations of genistein and daidzein, these dietary supplements alone did not lower PSA levels in men with low-volume prostate cancer.
UR - http://www.scopus.com/inward/record.url?scp=78249240074&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78249240074&partnerID=8YFLogxK
U2 - 10.1080/01635581.2010.492085
DO - 10.1080/01635581.2010.492085
M3 - Article
C2 - 21058191
AN - SCOPUS:78249240074
VL - 62
SP - 1036
EP - 1043
JO - Nutrition and Cancer
JF - Nutrition and Cancer
SN - 0163-5581
IS - 8
ER -